Cyclacel Enters Into a $20 Million Common Stock Purchase Agreement With Aspire Capital Fund, LLC

[at noodls] – Proceeds to Advance SEAMLESS, the Ongoing Phase 3 Trial of Sapacitabine in Elderly Patients With Newly Diagnosed AML BERKELEY HEIGHTS, N.J., Dec. 17, 2012 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, … more

View todays social media effects on CYCCP

View the latest stocks trending across Twitter. Click to view dashboard

See who Cyclacel is hiring next, click here to view